Reactive oxidative species (ROS)-based nanomedicine for BBB crossing and glioma treatment: current status and future directions

Frontiers in Immunology

Immunology

Shuqiu Zhou¹  Dandan Wu²  Bin Li²  Xuehui Chen³ 

[1] Department of Geriatrics, The Fourth Hospital of Daqing, Daqing, China;Department of Radiology, The First People’s Hospital of Linping District, Hangzhou, China;Department of Radiology, Tongjiang People’s Hospital, Tongjiang, China;

关键词: reactive oxygen species (ROS);    nanomedicine;    glioma;    blood-brain barrier (BBB);    photodynamic therapy;   

DOI  :  10.3389/fimmu.2023.1241791

 received in 2023-06-17, accepted in 2023-08-21,  发布年份 2023

来源: Frontiers

【 摘 要 】

Glioma is the most common primary intracranial tumor in adults with poor prognosis. Current clinical treatment for glioma includes surgical resection along with chemoradiotherapy. However, the therapeutic efficacy is still unsatisfactory. The invasive nature of the glioma makes it impossible to completely resect it. The presence of blood-brain barrier (BBB) blocks chemotherapeutic drugs access to brain parenchyma for glioma treatment. Besides, tumor heterogeneity and hypoxic tumor microenvironment remarkably limit the efficacy of radiotherapy. With rapid advances of nanotechnology, the emergence of a new treatment approach, namely, reactive oxygen species (ROS)-based nanotherapy, provides an effective approach for eliminating glioma via generating large amounts of ROS in glioma cells. In addition, the emerging nanotechnology also provides BBB-crossing strategies, which allows effective ROS-based nanotherapy of glioma. In this review, we summarized ROS-based nanomedicine and their application in glioma treatment, including photodynamic therapy (PDT), photothermal therapy (PTT), chemodynamic therapy (CDT), sonodynamic therapy (SDT), radiation therapy, etc. Moreover, the current challenges and future prospects of ROS-based nanomedicine are also elucidated with the intention to accelerate its clinical translation.

【 授权许可】

Unknown   
Copyright © 2023 Wu, Chen, Zhou and Li